Hondroflex (Hondroflex)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceGlucosamine + chondroitin sulfateGlucosamine + chondroitin sulfate
Similar drugsTo uncover
  • ARTRA®
    pills inwards 
    Unipharm, Inc.     USA
  • Arthravir®-complex-INCAMFARM®
    capsules inwards 
    TRIVIUM-XXI, LLC     Russia
  • KONDRONOVO®
    capsules inwards 
    Panacea Biotech Co., Ltd.     India
  • Structum®
    capsules inwards 
    Pierre Fabre Medication Production     France
  • Tazan®
    pills inwards 
    MS-VITA, LLC     Russia
  • Tazan®
    pills inwards 
    MS-VITA, LLC     Russia
  • Teraflex®
    capsules inwards 
    BAYER, AO     Russia
  • Chondroglucose
    gel externally 
    SYNTHESIS, OJSC     Russia
  • Chondroglucose
    pills inwards 
    MS-VITA, LLC     Russia
  • Hondroflex
    capsules inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
    • Dosage form: & nbspCapsules.
    Composition:
    for 1 capsule:
    Glucosamine hydrochloride 250 mg
    Chondroitin Sodium Sulphate - 200 mg
    Auxiliary substances
    [mannitol, 70 mg
    magnesium stearate, - 5 mg
    Croscarmellose sodium - 20 mg
    (impellosis),
    talc] - 5 mg
    Capsules, hard gelatin
    (Housing:
    titanium dioxide -2,0000 %,
    azorubin -0,0205 %,
    Ponce 4R -0,0120 %,
    acetic acid -0,1500%,
    gelatin -to 100%,
    Cap:
    titanium dioxide -2,0000 %,
    acetic acid -0,1500%,
    gelatin -100%)
    Average weight of capsule contents - 550 mg
    Description:Capsules number 0, body pink color, lid white. The contents of capsules are white or white powder with a yellowish tinge.
    Pharmacotherapeutic group:Reparation of tissue stimulant.
    ATX: & nbsp

    M.01.A.X   Other non-steroidal anti-inflammatory drugs

    Pharmacodynamics:
    Stimulates the restoration of cartilaginous tissue. Glucosamine and chondroitin sulfate participate in the synthesis of connective tissue, contributing to the prevention of cartilage destruction processes and stimulating the regeneration of tissue. The introduction of exogenous glucosamine enhances the production of the cartilaginous matrix and provides non-specific protection against chemical damage to the cartilage. Glucosamine in the form of a sulfate salt is a precursor of hexosamine, and the sulfate anion is necessary for the synthesis of glycosaminoglycans. Another possible function of glucosamine is to protect the damaged cartilage from metabolic destruction caused by non-steroidal anti-inflammatory drugs (HDL) and glucocorticosteroids (GCS), as well as its own moderate anti-inflammatory effect.
    Chondroitin sulfate, regardless of whether it is absorbed in intact form or as separate components, serves as an additional substrate for the formation of a healthy cartilage matrix.Stimulates the formation of hyaluronone, the synthesis of proteoglycans and collagen type II, and also protects hyaluronone from enzymatic cleavage (by suppressing the activity of hyaluronidase) and the damaging effect of free radicals; affects the phosphoric-calcium metabolism in the cartilaginous tissue, slows the resorption of bone tissue and reduces the loss of calcium, accelerates the processes of bone repair, inhibits the degeneration of cartilaginous tissue, helps restore the joint bag, cartilage surfaces of the joints, maintains the viscosity of the synovial fluid, plays the role of a kind of lubrication of the joint surfaces, is involved in cartilage repair and inhibits the activity of those enzymes that break down cartilage (elastase, hyaluronidase). In the treatment of osteoarthritis, it alleviates the symptoms of the disease and reduces the need for NSAIDs.
    Pharmacokinetics:

    When ingested 90% is absorbed from the gastrointestinal tract (GIT). The maximum concentration in the blood plasma (Cmax) is achieved after 3-4 hours, in synovial fluid - after 4-5 hours Bioavailability in relation to the synovial fluid:

    - for chondroitin-13%;

    - for glucosamine - 25% (the effect of "first passage" through the liver is expressed).

    When ingestion of chondroitin sodium sulfate once in a dose of 0.8 g (or twice a day at a dose of 0.4 g), the concentration in the plasma increases dramatically over a period of 24 hours. Absolute bioavailability is 12%.

    Glucosamine +chondroitin sulfate is distributed in tissues: the highest concentrations are found in the liver, kidneys and articular cartilage. About 30% of the dose is persistently persistent in bone and muscle tissue. About 10 and 20% of the dose received is absorbed in the form of high molecular weight and low molecular weight derivatives, respectively. The apparent volume of distribution is about 0.44 ml / g.

    Chondroitin sodium sulfate is metabolized by desulfurization (after administration of low molecular weight chondroitin sodium sulfate). When distributed in tissues, the highest concentrations are found in the liver, kidneys and articular cartilage. About 30% of the dose is persistently persistent in bone and muscle tissue. Glucosamine +chondroitin sulfate is excreted mainly with urine in unchanged form; in part - with feces.

    The half-life (T1/2) for glucosamine - 68 hours. Half-life (T1/2) for chondroitin sulfate - 310 min.

    Indications:Osteoarthrosis of peripheral joints and spine joints of I-III degree.
    Contraindications:Increased individual sensitivity to one of the components of the drug (allergic reaction), pronounced impaired kidney function, pregnancy, lactation, children under 18 years of age.
    Pregnancy and lactation:The drug is contraindicated for use during pregnancy and breastfeeding. If it is necessary to use the drug during lactation, it is recommended to stop breastfeeding.
    Dosing and Administration:Inside, 20 minutes before eating, with a small amount of liquid. Assign 2 capsules 3 times a day for the first three weeks; in the following days - 2 capsules 2 times a day. The minimum course of admission is 3 months.
    Side effects:Glucosamine: dysfunction of the gastrointestinal (epigastric pain, bloating, diarrhea or constipation), dizziness, allergic reactions, headache, leg pain and peripheral edema, lethargy, insomnia, tachycardia.
    Chondroitin: an allergic reaction.
    Overdose:
    Symptoms: cases of overdose are unknown.
    Treatment: gastric lavage, symptomatic therapy.
    Interaction:
    Increases the absorption of tetracyclines, reduces the effect of semisynthetic penicillins and glucosamine.
    The drug is compatible with NSAIDs and GCS.
    Special instructions:
    If unwanted effects on the part of the gastrointestinal tract appear, the dose should be reduced 2-fold, and if there is no improvement, cancel the drug. If there is no clinical effect after a treatment course of 4 capsules per day for 4 weeks, the diagnosis should be clarified.
    Do not exceed the dose recommended by your doctor.
    Stable therapeutic effect is achieved with a minimum of 6 months. Against the background of taking the drug, the need for NSAIDs decreases.
    Form release / dosage:Capsules 250 mg + 200 mg.
    Packaging:
    For 5, 6, 10 capsules in a contour mesh box made of polyvinylchloride film and foil of aluminum printed lacquered or 30, 60, 100 capsules in a glass or polymer jar.
    By 1,2, 3,4, 5, 6,9,10,12 contour cell packs with instructions for use in a pack of cardboard.
    Bank with instructions for use in a pack of cardboard.
    Storage conditions:In a dry, protected from light place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:
    2 years.
    Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:LP-000302
    Date of registration:17.02.2011
    Date of cancellation:2016-02-17
    The owner of the registration certificate:OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp28.09.2015
    Illustrated instructions
      Instructions
      Up